What is RSA?
Headquartered in North Carolina, RSA operates as an independent service organization dedicated to the lifecycle management of complex radiotherapy equipment. Since its inception in 1995, the company has carved out a niche in the maintenance, repair, and logistical support of external beam linear accelerators, commonly known as LINACs. By providing high-quality, cost-effective alternatives to original equipment manufacturer service contracts, RSA ensures that oncology departments maintain operational continuity. Their expertise in equipment installation and decommissioning further positions them as a vital partner for hospitals and cancer centers seeking to optimize their medical imaging and treatment assets.
How much funding has RSA raised?
RSA has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in RSA
PPP
Public-Private Partnership
What's next for RSA?
With the successful acquisition of $0, RSA is well-positioned to scale its service footprint and enhance its technical support infrastructure. The company's late-stage funding status suggests a focus on market consolidation and the potential expansion of its service portfolio to include emerging radiotherapy technologies. As the demand for precise oncology treatment grows globally, RSA's ability to provide reliable, independent maintenance will likely serve as a key competitive advantage. Future strategic initiatives will likely prioritize the integration of advanced diagnostic tools and the expansion of their technical workforce to meet the increasing complexity of modern LINAC systems.
See full RSA company page
